A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

NCT07430202 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))

Interventions

DRUG: DNAJB1-PRKACA Peptide Vaccine
DRUG: DRP-104
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]
[object Object]